Harvard Bioscience vs Owlet
HBIO and OWLT side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HBIO and OWLT compare
Owlet is the larger company, worth 2.4 times as much as Harvard Bioscience ($101M against $42.7M).
Owlet grew revenue faster over the last twelve months (13.9% versus 2.3% for Harvard Bioscience).
Owlet keeps more of each dollar of sales as profit, with a net margin of −10.2% compared with −13.2% at Harvard Bioscience.
Owlet scores higher on the StockData Score (8 against 3 for Harvard Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HBIO | OWLT |
|---|---|---|
| Size and price | ||
| Market cap | $42.7M | $101M |
| Share price | $9.39 | $3.44 |
| Change, 1 year | 50.9% | −68.7% |
| Change, 5 years | −87.4% | −93.9% |
| Beta (5Y) | 1.39 | 1.77 |
| Employees | 339 | 108 |
| StockData Score | ||
| Total score | 3 | 8 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 4 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.5× (better) | 0.9× |
| P/B | 8.4× | 3.8× (better) |
| FCF yield | −7.4% | −4.5% (better) |
| Fair value | – | $7.31 |
| Margin of safety | – | 52.9% |
| Growth | ||
| Revenue growth (TTM) | 2.3% | 13.9% (better) |
| Revenue growth, 5Y average | −3.3% | 7.1% (better) |
| Profitability | ||
| Gross margin | 57.4% (better) | 55.7% |
| Operating margin | −1.8% (better) | −6.4% |
| Net margin | −13.2% | −10.2% (better) |
| FCF margin | −3.5% (better) | −4.0% |
| Return on equity | −123% | – |
| Return on invested capital | −5.6% | – |
| Financial health | ||
| Debt / equity | 7.28 | 0.42 (better) |
| Interest coverage | – | −155.2× |
| Current ratio | 1.76 | 1.91 (better) |
| Altman Z-score | −2.36 | −2.07 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 36.9% | 58.2% |
| Insider net buying, 12 months | $202K (better) | −$296K |
Go deeper
- HBIO stock overview
- HBIO income statement
- HBIO valuation and score
- OWLT stock overview
- OWLT income statement
- OWLT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.